Search
Afizagabar
go.drugbank.com/drugs/DB21439InvestigationalAfizagabar is a small molecule drug. Afizagabar is under investigation in clinical trial NCT02877615 (Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event).
tgAAVCF
go.drugbank.com/drugs/DB17849InvestigationalIt is being investigated for the treatment of cystic fibrosis.[A259821, A259826] … tgAAVCF is an adeno-associated virus (AAV) vector encoding the human cystic fibrosis transmembrane conductance regulator protein (CFTR) cDNA.
Fluciclatide
go.drugbank.com/drugs/DB14842InvestigationalThe conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms … Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.
Squaric acid dibutyl ester
go.drugbank.com/drugs/DB12223InvestigationalSquaric acid dibutyl ester is under investigation in clinical trial NCT01971385 (Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis).
HKI-357
go.drugbank.com/drugs/DB13002InvestigationalHki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).
Coagulation factor XIa
go.drugbank.com/drugs/DB15420InvestigationalCoagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalXenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558]. … XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma].
MVC-COV1901
go.drugbank.com/drugs/DB15854InvestigationalAs of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210). … MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein.
GDC-0425
go.drugbank.com/drugs/DB14791InvestigationalGDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory
Inarigivir soproxil
go.drugbank.com/drugs/DB15063InvestigationalInarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic